Overview

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Status:
Active, not recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of Lazertinib when given orally to participants with epidermal growth factor receptor single activating mutation positive (EGFRm+) locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborator:

Yuhan Corporation

Treatments:

Lazertinib
Mitogens